Launch and Postlaunch Price Developments of New Drugs in the US, Germany, and Switzerland
- 1 November 2024
- journal article
- research article
- Published by American Medical Association (AMA) in JAMA Health Forum
- Vol. 5 (11) , e244461
Abstract
High prices of new drugs are concerning worldwide. In the US, overall drug spending between 2021 and 2022 grew by 9.4%, with a total of approximately $635.5 billion in 2022.1 Similar trends can be observed in European countries. For example, in Germany and Switzerland, drug expenditure increased by 5.2% and 6.5%, respectively, between 2021 and 2022.2,3 Drug prices are associated with these increasing costs.4Keywords
This publication has 16 references indexed in Scilit:
- Clinical Benefit and Regulatory Outcomes of Cancer Drugs Receiving Accelerated ApprovalJAMA, 2024
- The cancer premium – explaining differences in prices for cancer vs non-cancer drugs with efficacy and epidemiological endpoints in the US, Germany, and Switzerland: a cross sectional studyeClinicalMedicine, 2023
- Negotiating Drug Prices in the US—Lessons From EuropeJAMA Health Forum, 2022
- Getting the Price Right: Lessons for Medicare Price Negotiation from Peer CountriesPharmacoEconomics, 2022
- Trends in Prescription Drug Launch Prices, 2008-2021JAMA, 2022
- Analysis of Launch and Postapproval Cancer Drug Pricing, Clinical Benefit, and Policy Implications in the US and EuropeJAMA Oncology, 2021
- Clinical Trial Evidence Supporting US Food and Drug Administration Approval of Novel Cancer Therapies Between 2000 and 2016JAMA Network Open, 2020
- Estimation of Medicare Part D Spending on Insulin for Patients With Diabetes Using Negotiated Prices and a Defined FormularyJAMA Internal Medicine, 2020
- Changes in List Prices, Net Prices, and Discounts for Branded Drugs in the US, 2007-2018JAMA, 2020
- Prescription Drugs—List Price, Net Price, and the Rebate Caught in the MiddleJAMA, 2019